Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction
While immune cell therapies have transformed cancer treatment, achieving comparable success in solid tumors remains a significant challenge compared to hematologic malignancies like non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Over the past four decades, various immunotherapeutic strategies...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Cell Insight |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772892725000252 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422475057692672 |
|---|---|
| author | Huajian Tian Guifei Li Cookson K.C. Chiu E. Li Yuzong Chen Ting Zhu Min Hu Yanjie Wang Suping Wen Jiajia Li Shuangxue Luo Zhicheng Chen Huimei Zeng Nan Zheng Jinyong Wang Weijun Shen Xi Kang |
| author_facet | Huajian Tian Guifei Li Cookson K.C. Chiu E. Li Yuzong Chen Ting Zhu Min Hu Yanjie Wang Suping Wen Jiajia Li Shuangxue Luo Zhicheng Chen Huimei Zeng Nan Zheng Jinyong Wang Weijun Shen Xi Kang |
| author_sort | Huajian Tian |
| collection | DOAJ |
| description | While immune cell therapies have transformed cancer treatment, achieving comparable success in solid tumors remains a significant challenge compared to hematologic malignancies like non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Over the past four decades, various immunotherapeutic strategies, including tumor vaccines, tumor-infiltrating lymphocyte (TIL) therapies, and T cell receptor (TCR) therapies, have demonstrated clinical efficacy in select solid tumors, suggesting potential advantages over CAR-T and CAR-NK cell therapies in specific contexts. The dynamic nature of the cancer-immunity cycle, characterized by the continuous evolution of tumor-specific neoantigens, enables tumors to evade immune surveillance. This highlights the urgent need for rapid and accurate identification of functional tumor neoantigens to inform the design of personalized tumor vaccines. These vaccines can be based on mRNA, dendritic cells (DCs), or synthetic peptides. In this study, we established a novel platform integrating immunoprecipitation-mass spectrometry (IP-MS) for efficient and direct identification of tumor-specific neoantigen peptides. By combining this approach with our proprietary AI-based prediction algorithm and high-throughput in vitro functional validation, we can generate patient-specific neoantigen candidates within six weeks, accelerating personalized tumor vaccine development. |
| format | Article |
| id | doaj-art-fff515f3656c4a1da625ef4366eec90e |
| institution | Kabale University |
| issn | 2772-8927 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Insight |
| spelling | doaj-art-fff515f3656c4a1da625ef4366eec90e2025-08-20T03:31:05ZengElsevierCell Insight2772-89272025-06-014310025110.1016/j.cellin.2025.100251Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm predictionHuajian Tian0Guifei Li1Cookson K.C. Chiu2E. Li3Yuzong Chen4Ting Zhu5Min Hu6Yanjie Wang7Suping Wen8Jiajia Li9Shuangxue Luo10Zhicheng Chen11Huimei Zeng12Nan Zheng13Jinyong Wang14Weijun Shen15Xi Kang16Translation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaMulti-omics Mass Spectrometry Core, Biomedical Research Core Facilities, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaMulti-omics Mass Spectrometry Core, Biomedical Research Core Facilities, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaInstitute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China; The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, Guangdong, ChinaThe State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, Guangdong, ChinaGenomics core, Biomedical Research Core Facilities, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaGenomics core, Biomedical Research Core Facilities, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, ChinaInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China; Shenzhen International Institute for Biomedical Research, Shenzhen 518038, Guangdong, ChinaTranslation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China; Corresponding author.Translation Innovation center, Shenzhen Bay Laboratory, Shenzhen 518132, Guangdong, China; Corresponding author.While immune cell therapies have transformed cancer treatment, achieving comparable success in solid tumors remains a significant challenge compared to hematologic malignancies like non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Over the past four decades, various immunotherapeutic strategies, including tumor vaccines, tumor-infiltrating lymphocyte (TIL) therapies, and T cell receptor (TCR) therapies, have demonstrated clinical efficacy in select solid tumors, suggesting potential advantages over CAR-T and CAR-NK cell therapies in specific contexts. The dynamic nature of the cancer-immunity cycle, characterized by the continuous evolution of tumor-specific neoantigens, enables tumors to evade immune surveillance. This highlights the urgent need for rapid and accurate identification of functional tumor neoantigens to inform the design of personalized tumor vaccines. These vaccines can be based on mRNA, dendritic cells (DCs), or synthetic peptides. In this study, we established a novel platform integrating immunoprecipitation-mass spectrometry (IP-MS) for efficient and direct identification of tumor-specific neoantigen peptides. By combining this approach with our proprietary AI-based prediction algorithm and high-throughput in vitro functional validation, we can generate patient-specific neoantigen candidates within six weeks, accelerating personalized tumor vaccine development.http://www.sciencedirect.com/science/article/pii/S2772892725000252NeoantigenTumor vaccineMass spectrometryNew algorithm |
| spellingShingle | Huajian Tian Guifei Li Cookson K.C. Chiu E. Li Yuzong Chen Ting Zhu Min Hu Yanjie Wang Suping Wen Jiajia Li Shuangxue Luo Zhicheng Chen Huimei Zeng Nan Zheng Jinyong Wang Weijun Shen Xi Kang Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction Cell Insight Neoantigen Tumor vaccine Mass spectrometry New algorithm |
| title | Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction |
| title_full | Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction |
| title_fullStr | Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction |
| title_full_unstemmed | Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction |
| title_short | Rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction |
| title_sort | rapid and direct discovery of functional tumor specific neoantigens by high resolution mass spectrometry and novel algorithm prediction |
| topic | Neoantigen Tumor vaccine Mass spectrometry New algorithm |
| url | http://www.sciencedirect.com/science/article/pii/S2772892725000252 |
| work_keys_str_mv | AT huajiantian rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT guifeili rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT cooksonkcchiu rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT eli rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT yuzongchen rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT tingzhu rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT minhu rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT yanjiewang rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT supingwen rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT jiajiali rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT shuangxueluo rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT zhichengchen rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT huimeizeng rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT nanzheng rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT jinyongwang rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT weijunshen rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction AT xikang rapidanddirectdiscoveryoffunctionaltumorspecificneoantigensbyhighresolutionmassspectrometryandnovelalgorithmprediction |